ClinicalTrials.gg
CompletedNCT01242488Updated Jul 17, 2024

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

A Phase 2 interventional study of CDP6038 and CDP6038 in Rheumatoid Arthritis, sponsored by UCB Pharma. Completed at 82 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
5th of 10
221 · median 206
Started
2010
the only one that year
Phase 2
4 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
UCB Pharma

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 2, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

Read the detailed description

CDP6038 is a protein (antibody) that blocks interleukin-6 (IL-6), a substance involved in the inflammation associated with rheumatoid arthritis. This is a multicenter, 12-week, randomized, double-blind, placebo- and active- controlled study comparing several doses and dosage regimens (every 2 weeks and every 4 weeks) of CDP6038 to placebo and tocilizumab in patients with active rheumatoid arthritis who have had an unsuccessful response to methotrexate and previous anti-TNF therapy. The study will test if CDP6038 is more efficacious than placebo in reducing the signs and symptoms of rheumatoid arthritis at 12 weeks while maintaining an adequate safety profile. In order to maintain the study blinding all subjects will be given a subcutaneous (sc) injection (under the skin) every 2 weeks, as well as an intravenous (iv) infusion every 4 weeks. In addition subjects must remain on stable weekly doses of methotrexate. Assessments during the study include evaluations of joint pain and swelling, laboratory blood and urine tests, physical examinations, vital signs, electrocardiograms, and questionnaires. Subjects who complete the 12-week study will be eligible to enroll in a long-term extension study receiving CDP6038.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • CDP6038
  • Interleukin-6
  • Tocilizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of rheumatoid arthritis (according to the 1987 ACR classification criteria OR a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for rheumatoid arthritis ) for at least 6 months prior to screening
  • Must have been treated with MTX 12.5-25 mg/week, for at least 6 weeks prior to screening. Doses of 10 to \< 12.5mg/week are allowed if there is documented intolerance
  • Have moderately to severely active rheumatoid arthritis disease with at least 6 tender and 6 swollen joints
  • CRP ≥1.2 times the (central laboratory) or erythrocyte sedimentation rate of more than 28mm/hour
  • Intolerant or inadequate response to treatment (ie, TNF blocker failure)≥1 licensed TNF-blocker therapies within 2 years of screening

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of any other inflammatory arthritis or secondary, noninflammatory type of arthritis, such as psoriatic arthritis, lupus, gout, or ankylosing spondylitis
  • Wheelchair bound or bedridden.
  • Disease modifying antirheumatic drugs (DMARDs) other than MTX.
  • Treatment with tocilizumab or any other anti-IL-6 therapies at any time.
  • Treatment with other biologics within 4-24 weeks (depending on the biologic)
  • History of ongoing, chronic or recurrent infections or recent serious or life-threatening infection
  • Known concurrent acute or chronic viral or C infection or (HIV) infection.
  • Vaccinations (other than injectable influenza or pneumococcal) within 8 weeks prior to screening or plan to receive vaccines during the study
  • Concurrent or history of with the exception of nonmelanoma skin cancer successfully treated more than 2 years prior to screening or cervical cancer successfully treated more than 5 years prior to screening.
  • History of chronic alcohol abuse or drug addiction within the last 1 year or current drug addiction or use of illicit drugs.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    CDP6038 60 mg sc every 2 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo iv

  • Experimental
    CDP6038 60 mg sc every 4 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo sc · Other: Placebo iv

  • Experimental
    CDP6038 120 mg sc every 2 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo iv

  • Experimental
    CDP6038 120 mg sc every 4 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo sc · Other: Placebo iv

  • Experimental
    CDP6038 240 mg sc every 2 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo iv

  • Experimental
    CDP6038 240 mg sc every 4 weeks plus methotrexate

    Biological: CDP6038 · Other: Placebo sc · Other: Placebo iv

  • Active comparator
    Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate

    Biological: Tocilizumab (Actemra or RoActemra) · Other: Placebo sc

  • Placebo comparator
    Placebo sc every 2 weeks plus methotrexate

    Other: Placebo sc · Other: Placebo iv

  • Placebo comparator
    Placebo sc every 4 weeks plus methotrexate

    Other: Placebo sc · Other: Placebo iv

Interventions

  • BiologicalCDP6038

    60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10

  • BiologicalCDP6038

    120 mg sc at Weeks 0, 2, 4 6, 8, and 10

  • BiologicalCDP6038

    240 mg sc at Weeks 0, 2, 4 6, 8, and 10

  • 8 mg/kg intravenously (iv) at Weeks 0, 4 and 8

  • BiologicalCDP6038

    60 mg sc at Weeks 0, 4 and 8

  • BiologicalCDP6038

    240 mg sc at Weeks 0, 4 and 8

  • BiologicalCDP6038

    120 mg sc at Weeks 0, 4 and 8

  • OtherPlacebo sc

    0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10

  • OtherPlacebo sc

    0.9% Sodium chloride for injection at Weeks 2, 6 and 10

  • OtherPlacebo iv

    0.9% Sodium chloride for injection at Weeks 0, 4 and 8

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Disease Activity Score (C-reactive protein) [DAS28(CRP)] for CDP6038 and placebo

    Time frame: Baseline, Week 12

Secondary outcomes

  1. American College of Rheumatology 20% response (ACR20) rates for the CDP6038 and placebo arms.

    Time frame: From Baseline to Week 12

  2. American College of Rheumatology 50% response (ACR50) rates for the CDP6038 and placebo arms.

    Time frame: From Baseline to Week 12

  3. American College of Rheumatology 70% response (ACR70) rates for the CDP6038 and placebo arms.

    Time frame: From Baseline to Week 12

07

Study locations

82 sites
  • 166
    Mesa, Arizona, United States
  • 154
    Paradise Valley, Arizona, United States
  • 118
    Scottsdale, Arizona, United States
  • 103
    Hot Springs, Arkansas, United States
  • 125
    Jonesboro, Arkansas, United States
  • 127
    Covina, California, United States
  • 148
    La Jolla, California, United States
  • 184
    Long Beach, California, United States
  • 177
    Los Angeles, California, United States
  • 104
    Palo Alto, California, United States
  • 149
    Sacramento, California, United States
  • 158
    San Diego, California, United States
  • 129
    Santa Maria, California, United States
  • 164
    Upland, California, United States
  • 107
    Wildomar, California, United States
  • 141
    Hamden, Connecticut, United States
  • 137
    Norwalk, Connecticut, United States
  • 101
    Trumbull, Connecticut, United States
  • 111
    Lewes, Delaware, United States
  • 176
    Aventura, Florida, United States
  • 186
    Daytona Beach, Florida, United States
  • 151
    DeBary, Florida, United States
  • 114
    Jupiter, Florida, United States
  • 183
    Pinellas Park, Florida, United States
  • 178
    Sarasota, Florida, United States
  • 140
    South Miami, Florida, United States
  • 157
    Tampa, Florida, United States
  • 130
    Gainesville, Georgia, United States
  • 162
    Newnan, Georgia, United States
  • 153
    Savannah, Georgia, United States
  • 113
    Stockbridge, Georgia, United States
  • 116
    Idaho Falls, Idaho, United States
  • 160
    Moline, Illinois, United States
  • 156
    Rock Island, Illinois, United States
  • 168
    Springfield, Illinois, United States
  • 133
    Cedar Rapids, Iowa, United States
  • 172
    Kansas City, Kansas, United States
  • 185
    Saint Clair Shores, Michigan, United States
  • 112
    Saint Louis, Missouri, United States
  • 134
    Saint Louis, Missouri, United States
  • 102
    Lincoln, Nebraska, United States
  • 171
    Freehold, New Jersey, United States
  • 163
    New Brunswick, New Jersey, United States
  • 152
    Toms River, New Jersey, United States
  • 174
    Brooklyn, New York, United States
  • 115
    Rochester, New York, United States
  • 109
    Belmont, North Carolina, United States
  • 170
    Charlotte, North Carolina, United States
  • 150
    Cincinnati, Ohio, United States
  • 108
    Columbus, Ohio, United States
  • 100
    Dayton, Ohio, United States
  • 110
    Oklahoma City, Oklahoma, United States
  • 165
    Duncansville, Pennsylvania, United States
  • 117
    Wexford, Pennsylvania, United States
  • 105
    Nashville, Tennessee, United States
  • 106
    Nashville, Tennessee, United States
  • 120
    Amarillo, Texas, United States
  • 135
    Austin, Texas, United States
  • 128
    Dallas, Texas, United States
  • 126
    Houston, Texas, United States
  • 132
    Houston, Texas, United States
  • 138
    Houston, Texas, United States
  • 181
    Houston, Texas, United States
  • 145
    Mesquite, Texas, United States
  • 143
    Nassau Bay, Texas, United States
  • 122
    San Antonio, Texas, United States
  • 144
    Tomball, Texas, United States
  • 142
    Victoria, Texas, United States
  • 121
    Salt Lake City, Utah, United States
  • 139
    Chesapeake, Virginia, United States
  • 119
    Seattle, Washington, United States
  • 175
    Tacoma, Washington, United States
  • 136
    Beckley, West Virginia, United States
  • 167
    Clarksburg, West Virginia, United States
  • 401
    Brussels, Belgium
  • 400
    Liege, Belgium
  • 209
    Torquay, Devon, United Kingdom
  • 201
    Wigan, Lancashire, United Kingdom
  • 206
    Essex, United Kingdom
  • 205
    London, United Kingdom
  • 204
    Newcastle Upon Tyne, United Kingdom
  • 208
    Southampton, United Kingdom
08

References and documents

Publications

  • Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18. PubMed 24641941 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Nov 17, 2010
Start
Nov 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results delay requested
Jan 25, 2013
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01242488
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Nov 17, 2010
Start date
Nov 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Jul 17, 2024

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion